Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.09 | — | — | — | — | 10.16 | 0.42 | — | — | — | — | — | — | — | — | — | — | 10.82 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.45 | 68.48 | 32.27 | 36.06 | 14.07 | 1.35 | 0.16 | 1.09 | 0.38 | 0.46 | 0.89 | 3.26 | 18.41 | 44.20 | 61.48 | 382.83 | 21.71 | 3.85 | 31.98 | 50.85 | 78.00 |
| — | +4966.0% | +19555.1% | +3220.4% | +3627.1% | +196.6% | -81.6% | -66.7% | -97.9% | -99.0% | -98.5% | -99.1% | -15.2% | +1049.3% | +92.2% | +652.9% | -72.2% | -95.8% | -65.4% | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | 22.70 | 4.64 | 2.67 | 2.07 | 3.08 | 4.17 | 5.49 | 5.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +636.6% | +11.3% | -51.3% | -61.7% | -28.7% | +26.7% | +51.6% | +81.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 6.98 | 0.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.21 | — | — | — | — | 7.12 | 0.58 | — | — | — | — | — | — | — | — | — | — | 10.58 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.4% | 69.7% | 76.0% | 93.5% | 96.7% | 96.8% | 79.2% | 79.3% | 81.1% | 83.8% | 92.7% | 25.7% | -22.3% | -202.5% | 82.4% | -27036.2% | 100.0% | 100.0% | 100.0% | -948.4% | 100.0% |
| — | -28.0% | -4.0% | +17.9% | +19.2% | +15.5% | -14.6% | +208.6% | +463.4% | +141.4% | +12.6% | +100.1% | -122.3% | -302.5% | -17.6% | -2750.7% | 0.0% | +106.0% | +105.9% | — | — | |
| Operating Margin | 29.7% | -749.2% | -652.9% | -160.7% | -103.5% | 18.2% | 39.5% | -37.3% | -54.1% | -63.7% | -114.2% | -1253.0% | -3255.9% | -7462.3% | -6118.9% | -34180.5% | -1897.8% | -62.3% | -1206.2% | -1237.5% | -1579.4% |
| — | -4218.6% | -1751.5% | -331.3% | -91.2% | +128.6% | +134.6% | +97.0% | +98.3% | +99.1% | +98.1% | +96.3% | -71.6% | -11878.6% | -407.3% | -2662.2% | -20.2% | +97.1% | +45.2% | — | — | |
| Net Margin | 27.1% | -767.3% | -803.3% | -213.5% | -124.6% | 13.6% | 38.7% | -38.8% | -54.5% | -66.5% | -116.1% | -1421.7% | -3264.6% | -7430.3% | -6098.8% | -33743.0% | -1885.9% | 35.8% | -1204.6% | -1236.7% | -1576.6% |
| — | -5749.5% | -2174.3% | -451.0% | -128.6% | +120.4% | +133.4% | +97.3% | +98.3% | +99.1% | +98.1% | +95.8% | -73.1% | -20854.2% | -406.3% | -2628.4% | -19.6% | +101.7% | +45.4% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | -196.4% | -78.0% | -47.5% | -37.8% | 7.7% | -35.0% | -31.7% | -26.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -2662.0% | -123.2% | -50.2% | -43.4% | +133.4% | -92.3% | -58.9% | -30.4% | |
| ROA | 50.5% | -23.6% | -20.6% | -13.5% | -12.8% | 4.8% | 44.4% | -10.1% | -16.9% | -13.5% | -19.2% | -34.1% | -32.1% | -25.9% | -22.0% | -20.0% | -20.9% | 4.4% | -20.4% | -20.3% | -18.7% |
| — | -588.5% | -146.4% | -34.1% | +23.9% | +135.8% | +331.4% | +70.5% | +47.5% | +48.0% | +12.9% | -70.4% | -53.4% | -685.1% | -8.2% | +1.5% | -12.0% | +126.1% | -45.3% | -24.3% | -4.7% | |
| ROIC | 462.6% | — | — | -17.4% | -16.5% | — | — | — | — | — | — | — | — | -110.0% | -63.7% | -39.3% | -29.3% | -12.3% | -38.7% | -33.1% | -28.8% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -791.9% | -64.7% | -18.7% | -1.5% | +53.0% | -77.2% | -57.0% | -60.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.68 | 0.85 | 0.57 | 0.33 | 0.25 | 0.08 | 0.10 | 0.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +3392.5% | +986.6% | +460.0% | +311.9% | +576.5% | +147.0% | +211.1% | +113.6% | |
| Debt / EBITDA | 1.39 | — | — | — | — | 5.15 | 1.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.82 | 1.98 | 2.16 | 0.82 | 1.02 | 1.70 | 0.57 | 0.48 | 0.59 | 0.42 | 0.59 | 0.72 | 1.50 | 2.31 | 3.30 | 3.74 | 3.92 | 5.28 | 3.10 | 3.64 | 4.29 |
| — | +16.2% | +279.9% | +69.7% | +73.3% | +304.1% | -3.6% | -32.7% | -60.8% | -81.8% | -82.2% | -80.8% | -61.7% | -56.2% | +6.7% | +2.8% | -8.7% | +19.6% | -43.9% | -42.4% | -54.4% | |
| Quick Ratio | 0.82 | 1.98 | 2.16 | 0.82 | 1.02 | 1.70 | 0.57 | 0.40 | 0.50 | 0.29 | 0.50 | 0.65 | 1.42 | 2.21 | 3.22 | 3.72 | 3.92 | 5.28 | 3.10 | 3.64 | 4.29 |
| — | +16.2% | +279.9% | +103.1% | +104.5% | +477.6% | +13.5% | -37.8% | -64.8% | -86.7% | -84.5% | -82.6% | -63.8% | -58.2% | +4.2% | +2.3% | -8.7% | +19.6% | -43.9% | -42.4% | -54.4% | |
| Interest Coverage | 9.63 | -24.30 | -3.99 | -2.81 | -3.70 | 3.46 | 38.37 | -11.50 | -17.53 | -14.09 | -26.52 | -50.39 | -49.05 | -50.60 | -54.95 | — | -682.59 | 144.15 | -22025.25 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATRA stock.
Atara Biotherapeutics, Inc.'s current P/E is -7.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Atara Biotherapeutics, Inc.'s current operating margin is 29.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Atara Biotherapeutics, Inc.'s business trajectory between earnings reports.